Sanofi India managing director N Rajaram and ex-GSK executive Salil Kallianpur discuss with Scrip a range of aspects around pharma’s digitization efforts including getting the "outside" talent mix right, avoiding digital "intrusion" in physician engagement and the impact of the surge in teleconsultation.

Scrip and Pink Sheet editors join Datamonitor Healthcare analysts to discuss Biogen's Aduhelm for Alzheimer's disease, including the expected launch trajectory, early commercial barriers to uptake and the Medicare reimbursement environment.

In this week's podcast edition of Five Must-Know Things: J&J’s outlook for coronavirus vaccines; Cosentyx comes in strong for Novartis; Biogen’s views on Aduhelm pricing; competition in the “dustat” sector; and dealing with endemic COVID-19.

In this week's podcast edition of Five Must-Know Things: pharma’s Q2 prospects; Bayer’s plans for the US launch of its CKD drug; big tobacco takes further steps into healthcare; KRAS’s emergence in oncology amid ongoing challenges; and tips for European biotech fundraising.

In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.

In this week's podcast edition of Five Must-Know Things: vaccine efficacy and the Delta and Delta Plus variants; breakthroughs in CRISPR gene editing and microbiome therapies; and the pandemic’s possible effect on regulatory pathways.

In this week's podcast edition of Five Must-Know Things: a look at pharma CEO pay; Pfizer’s CEO gives the inside track on COVID vaccine development; GSK elaborates on its restructuring and strategic plans; and Kite talks about its cell therapy plans under Gilead. 

In this audio interview, Organon’s head for the Asia Pacific region talks to Scrip on the company’s ambitions in the women’s health segment and the outlook for its biosimilars and established brands portfolios.